BrightGene Bio-Medical Technology (SHA:688166) secured the approval of China's medical products administrator for the listing of dopamine hydrochloride as a chemical active pharmaceutical ingredient.
dopamine hydrochloride is suitable for treating shock syndromes caused by myocardial infarction, trauma, endotoxin sepsis, heart surgery, kidney failure or congestive heart failure, according to a Tuesday filing with the Shanghai bourse.
Shares of the pharmaceutical company closed 2% lower Tuesday.